Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: Preliminary results of a prospective study

Transplant International

Volumn 25, Issue 1, 2012, Pages 41-47

  Capron, Arnaud ^a   Lerut, Jan ^a   Latinne, Dominique ^a   Rahier, Jacques ^a   Haufroid, Vincent ^a   Wallemacq, Pierre ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

intrahepatic concentration; liver transplantation; peripheral blood mononuclear cells; rejection; tacrolimus

Indexed keywords

LYMPHOCYTE ANTIBODY; R ATG; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL LEVEL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; END STAGE LIVER DISEASE; FEMALE; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM;

ADULT; AGED; COHORT STUDIES; DRUG MONITORING; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 83955165904     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01365.x     Document Type: Article

References (32)

1. Kaufman DB, Shapiro R, Lucey MR, et al. Immunosuppression: practice and trends. Am J Transplant 2004; 4 (Suppl 9): 38.
2. Staatz CE, Tett SE,. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623.
3. Winkler M, Ringe B, Baumann J, et al. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK506 for immunosuppression. Clin Chem 1994; 40: 2247.
4. Venkataramanan R, Shauw LM, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentration in liver transplant patients. J Clin Pharmacol 2001; 41: 542.
5. Kershner RP, Fitzsimmons WE,. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920.
6. Erden E, Warty V, Magnone M, et al. Plasma FK506 levels in patients with histopathologically documented renal allograft rejection. Transplantation 1994; 58: 397.
7. Japanese FK506 Study Group. Morphological characteristics of renal allografts showing renal dysfunction under FK506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK nephropathy? Transplant Proc 1993; 25: 624.
8. Capron A, Lerut J, Verbaandert C, et al. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection. Ther Drug Monit 2007; 29: 340.
9. Sandborn WJ, Lawson GM, Krom RA, et al. Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection. Hepatology 1992; 15: 1086.
10. Sandborn WJ, Lawson GM, Cody TJ, et al. Early cellular concentration after orthotopic liver transplantation correlates with low concentration of FK506 in hepatic tissue. Hepatology 1995; 21: 70.
11. Ansermot N, Fathi M, Veuthey JL, et al. Quantification of cyclosporine A in peripheral blood mononuclear cells by liquid chromatography-electrospray mass spectrometry using a column-switching approach. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 857: 92.
12. Crettol S, Venetz JP, Fontana M, et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics 2008; 18: 307.
13. Capron A, Musuamba F, Latinne D, et al. Validation of liquid-chromatography mass spectrometric assay for tacrolimus in peripheral blood mononuclear cells. Ther Drug Monit 2009; 31: 178.
14. Demetris A, Adams D, Bellamy C, et al. Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology 2000; 31: 792.
15. Höroldt BS, Burattin M, Gunson BK, et al. Does the Banff rejection activity index predict outcome in patients with early acute cellular rejection following liver transplantation? Liver Transpl 2006; 12: 1144.
16. Lerut J, Mathys J, Verbaandert C, et al. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. Ann Surg 2008; 248: 956.
17. Wallemacq P, Goffinet JS, O'Morchoe S, et al. Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. Ther Drug Monit 2009; 31: 198.
18. Bäckman L, Nicar M, Levy M, et al. FK506 through levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation 1994; 57: 519.
19. Böttiger Y, Brattstörm C, Tydén G, et al. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol 1999; 48: 445.
20. Langers P, Press RR, den Hartigh J, et al. Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration. Ther Drug Monit 2008; 30: 456.
21. Callaghan R, Crowley E, Potter S, et al. P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 2008; 48: 365.
22. Coons JS, Wang YZ, Bines SD, et al. Multidrug resistance P-glycoprotein in human lymphocytes. Hum Immunol 1991; 32: 134.
23. Chaudhray PM, Mechetner EB, Roninson IB,. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 134.
24. Ford J, Hoggard PG, Owen A, et al. A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. J Immunol Methods 2003; 274: 129.
25. Elens L, Capron A, Kerkckove VV, et al. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomics 2007; 17: 873.
26. Capron A, Mourad M, De Meyer M, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics 2010; 11: 703.
27. Hesselink DA, van Schaik RH, van der Heiden I, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR1-genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245.
28. Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76: 1233.
29. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147.
30. Kliewer SA,. The nuclear pregnan X receptor regulates xenobiotic detoxification. J Nutr 2003; 133: 2444S.
31. Lamba J, Lamba V, Schuetz E,. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 2005; 6: 369.
32. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005; 70: 949.